ZR202a-CoV / Walvax - LARVOL DELTA

Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty®: a randomized, observer-blind, controlled, phase 1 study. (PubMed, Int J Infect Dis) - "Similar reactogenicity and immunogenicity profiles of ZR-202-CoV, ZR-202a-CoV and Comirnaty® support further clinical investigation in a wider population."

Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults. (clinicaltrials.gov) - P1/2 | N=60 | Active, not recruiting | Sponsor: Shanghai Zerun Biotechnology Co.,Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Aug 2023

Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases